Methotrexate in rheumatoid arthritis
1988; Wiley; Volume: 31; Issue: 3 Linguagem: Inglês
10.1002/art.1780310301
ISSN1529-0131
AutoresDaniel E. Fürst, Joel M. Kremer,
Tópico(s)Autoimmune and Inflammatory Disorders Research
ResumoArthritis & RheumatismVolume 31, Issue 3 p. 305-314 Current CommentFree to Read Methotrexate in rheumatoid arthritis Daniel E. Furst MD, Corresponding Author Daniel E. Furst MD Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, and the Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, New York.Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, IA 52242Search for more papers by this authorJoel M. Kremer MD, Joel M. Kremer MD Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, and the Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, New York.Search for more papers by this author Daniel E. Furst MD, Corresponding Author Daniel E. Furst MD Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, and the Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, New York.Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, IA 52242Search for more papers by this authorJoel M. Kremer MD, Joel M. Kremer MD Division of Rheumatology, Department of Medicine, The University of Iowa, Iowa City, and the Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, New York.Search for more papers by this author First published: March 1988 https://doi.org/10.1002/art.1780310301Citations: 129AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Reference 1 Thompson RN, Watts C. Edelman J, Esdaile J, Russell AS: A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11: 760– 763, 1984 2 Weinblatt ME, Coblyn JS, Fox DA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818– 822, 1985 3 Williams HJ, Willkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger MJ, Reading JC, Ward JR: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 28: 721– 730, 1985 4 Kremer JM, Lee JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29: 822– 831, 1986 5 Weinblatt ME, Coblyn JS, Fraser PA, Holdsworth DE, Falchuk KR, Trentham DE: Long term prospective study of methotrexate in rheumatoid arthritis (abstract). Arthritis Rheum (suppl) 29 (4): S76, 1986 6 Kremer JM, Rynes RI, Bartholomew LE: Severe flare of rheumatoid arthritis after discontinuing long-term methotrexate therapy: a double blind study. Am J Med (in press) 7 Hoffmeister RT: Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med (suppl) 75: 69– 73, 1983 8 Willkens RF, Watson MA: Methotrexate: perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 100: 314– 321, 1982 9 Graff GD, Shenberger KN, Wilke WS, Taylor TH: Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 12: 333– 347, 1983 10 Weinstein A, Marlowe S, Korn J, Farouhar F: Low-dose methotrexate treatment of rheumatoid arthritis: long-term observations. Am J Med 79: 331– 337, 1985 11 Anderson PA, West SA, O'Dell Jr, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 103: 489– 496, 1985 12 Williams HJ For the Cooperative Systematic Studies of Rheumatic Diseases: Effect of increasing dose of methotrexate in patients with rheumatoid arthritis (abstract). Arthritis Rheum (suppl) 28: S87, 1985 13 Ridge SC, Rath N, Galivan J, Zabriskie J, Oronsky AL, Kerwar SS: Studies on the effect of D-penicillamine, gold thioglucose and methotrexate on streptococcal cell-wall arthritis. J Rheumatol 13: 895– 898, 1986 14 Dahl MG, Gregory MM, Scheuer PJ: Methotrexate hepatotoxicity in psoriasis: comparison of different dose regimens. Br Med J 1: 654– 656, 1972 15 Podurgiel BJ, McGill DB, Ludwig J, Taylor WF, Miller SA: Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 48: 787– 792, 1973 16 Furst DE, Haub R, Faulkner R, Hoffman J: Pharmaco-kinetics of low dose methotrexate in rheumatoid arthritis (abstract). Clin Pharmacol Ther 39: 193, 1986 17 Edelman J, Biggs DF, Fakhreddin J, Russell AS: Low dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 35: 382– 386, 1984 18 Condit PT, Chanes RE, Joel W: Renal toxicity of methotrexate. Cancer 23: 126– 131, 1969 19 Maiche AG: Acute renal failure due to concomitant action of methotrexate and indomethacin (letter). Lancet 11: 1390, 1986 20 Thomas MH, Gutterman LA: Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 13: 440– 441, 1986 21 Daly H, Boyle J, Roberts C, Scott G: Interaction between methotrexate and non-steroidal anti-inflammatory drugs (letter). Lancet 1: 557, 1986 22 Thyss A, Milano G, Kubar J, Namer M, Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256– 258, 1986 23 Kates RE, Tozer TN, Sorby DL: Increased methotrexate toxicity due to concurrent probenecid administration. Biochem Pharmacol 25: 1485– 1488, 1976 24 Mandel MA: The synergistic effect of salicylates on methotrexate toxicity. Plast Reconstr Surg 57: 733– 737, 1976 25 Mihranian MH, Wang YM, Daly JM: Effects of nutritional depletion and repletion of plasma methotrexate pharmacokinetics. Cancer 54: 2268– 2271, 1984 26 Rooney TW, Furst DE: Comparison of toxicity in methotrexate treated rheumatoid arthritis patients also taking aspirin or other NSAID (abstract). Arthritis Rheum (suppl) 29 (4): S76, 1986 27 Nierenberg DW: Competitive inhibition of methotrexate accumulation in rabbit kidney slices by non-steroidal anti-inflammatory drugs. J Pharmacol Exp Ther 226: 1– 6, 1983 28 Wilke WS, Segal AM, Calabrese LH, MacKenzie AH, Scheetz RJ, White CS, Mazaner DJ, Clough JC: Twenty-four week double-blind cross-over study in methotrexate in rheumatoid arthritis (abstract). Clin Res 33: 884A, 1985 29 DiBartolomeo AG, Mayes MD, Bathon JM: Methotrexate in rheumatoid arthritis: a longitudinal study of liver biopsies (abstract). Arthritis Rheum (suppl) 27: S61, 1984 30 Gagliano RG, Costanzi JJ: Paraplegia following intrathecal methotrexate. Cancer 37: 1663– 1668, 1976 31 Martino RL, Benson AB III, Merritt JA, Brown JJ, Lesser Jr: Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 54: 2003– 2005, 1984 32 Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289: 770– 773, 1973 33 Duller P: The impact of methotrexate on psycho-organic functioning. Br J Dermatol 113: 503– 504, 1985 34 Nyfors A: Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 25: 208– 226, 1978 35 Jaffe N, Takane Y, Anzai T, Robertson R: Transient neurologic disturbances induced by high dose methotrexate treatment. Cancer 56: 1358– 1360, 1985 36 Krakower GR, Nylen PA, Kamen BA: Separation and identification of sub-picomole amounts of methotrexate polyglutamates in animal and human biopsy material. Anal Biochem 112: 412– 416, 1982 37 Winick J, Krakower GR, Kamen BA: Metabolism of methotrexate to polyglutamyl derivatives and the relationship to folate pools in vivo, Proceedings of the Second Workshop on Folyl and Anti-Folyl Polyglutamates. Edited by ID Goldman. New York, Praeger Scientific, 1985 38 Kremer JM, Galivan J, Streckfuss A, Kamen B: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29: 832– 835, 1986 39 Craft AW, Kay HEM, Lawson DN, McElwain TJ: Methotrexate-induced malabsorption in children with acute lymphoblastic leukemia. Br Med J 2: 1511– 1512, 1977 40 Pinkerton CR, Cameron CHS, Sloan JM, Glasgow JFT, Wevava NJT: Jejunal crypt cell abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukemia. J Clin Pathol 35: 1272– 1277, 1982 41 Cunningham D, Morgan RJ, Mills PR, Nelson LM, Toner PG, Soukop M, McArdle CS, Russell RI: Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 38: 265– 270, 1985 42 Pinkerton CR, Milla PJ: Methotrexate enterotoxicity: influence of drug dose and timing in the rat. Br J Cancer 49: 97– 101, 1984 43 Curd CD, Manno JE, Steward JJ: Effects of methotrexate on intestinal transit in rats. Fundam Appl Toxicol 5: 991– 996, 1985 44 Navarro M, Pedragosa R, Lafuerza A, Rubio D, Huguet P: Leukocytoclastic vasculitis after high-dose methotrexate. Ann Intern Med 105: 471– 472, 1986 45 Doyle LA, Berg C, Bottino G, Chabner B: Erythema and desquamation after high-dose methotrexate. Ann Intern Med 98: 611– 612, 1983 46 Lawrence CM, Dahl MB: Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J Am Acad Dermatol 11: 1059– 1065, 1984 47 Marks CR, Willkens RF, Wilske KR, Brown PB: Small-vessel vasculitis and methotrexate (letter). Ann Intern Med 100: 916, 1984 48 Karger T, Rau R: Methotrexate therapy of highly active polyarthritis, Rheumatology: An Annual Review. Vol. 9. Edited by R Rau. Basel, Karger, 1986, pp 154– 159 49 Van de Kerkhof PCM, Hoefnagels WHL, van Haelst JGM, Mali JWH: Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 10: 194– 200, 1985 50 Rau R, Karger T, Frenzel H: Liver biopsy findings in patients with rheumatoid arthritis and psoriatic arthritis on long-term treatment with methotrexate (abstract). Arthritis Rheum (suppl) 29 (4): S76, 1986 51 Chojkier M, Filip M: Hepatocyte collagen production in vivo in normal rats. J Clin Invest 78: 333– 339, 1986 52 Laine L, Chojkier M: Hepatic collagen production in the rat is unaffected by methotrexate. Proc Soc Exp Biol Med 182: 194– 200, 1986 53 Lanse SB, Arnold GL, Gowans JDC, Kaplan MM: Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis and rheumatoid arthritis. Dig Dis Sci 30: 104– 109, 1985 54 Tolman KG, Kremer JM, Lee RG, Mitros F, LaBrecque DE, Furst DE: Pretreatment liver histology in rheumatoid arthritis patients treated with low dose methotrexate (abstract). Arthritis Rheum (suppl) 29 (4): S18, 1986 55 Nyfors A: Liver biopsies for psoriasis related to methotrexate therapy: findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Immunol Scand 85: 511– 514, 1977 56 Aponte J, Petrelli M: Hepatic histology following prolonged treatment of rheumatoid arthritis with bolus methotrexate (abstract). Arthritis Rheum (suppl) 28: S37, 1985 57 Willkens RF, Clegg DO, Ward Jr, Marks CR, Greene ML, Tolman KG, Roth GJ, Jackson CG, Leonard PA: Liver biopsies in patients on low dose pulse methotrexate for the treatment of rheumatoid arthritis (abstract). Arthritis Rheum (suppl) 28: S77, 1985 58 Zachariae H, Kragballe K, Sogaard H: Methotrexate-induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 102: 407– 412, 1980 59 Robinson JK, Baughman RD, Auerback R, Cimis RJ: Methotrexate hepatotoxicity in psoriasis: consideration of liver biopsies at regular intervals. Arch Dermatol 116: 413– 415, 1980 60 Geronemus RG, Auerbach R, Tobias H: Liver biopsies versus liver scans in methotrexate-treated patients with psoriasis. Arch Dermatol 118: 649– 651, 1982 61 Miller JA, Dodd H, Rustin MHA, Lees WR, Levene GM, Kirby JD, Munro DD: Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis. Br J Dermatol 113: 699– 705, 1985 62 Weinblatt ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol (suppl) 12: 35– 38, 1985 63 Boh LE, Schuna AA, Pitterle ME, Adams EM, Sundstrom WR: Low-dose weekly oral methotrexate therapy for inflammatory arthritis. Clin Pharmacol 5: 503– 508, 1986 64 Furst DE, Zavala D, Monick M, Hauser M, Hunninghake G: Pulmonary function testing and bronchoalveolar lavage in rheumatoid arthritis patients on low dose methotrexate (abstract). Arthritis Rheum (suppl) 29 (4): S17, 1986 65 Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B: Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol 111: 273– 276, 1986 66 Henning H, Ibsen W: Electroencephalographic examination in seven patients treated with methotrexate for psoriasis. Acta Pharmacol Toxicol 58: 303– 304, 1986 67 IARC Working Group: Methotrexate. IARC Monogr Eval Carcinog Risk Chem Hum 26: 282– 285, 1982 68 Li JC, Kaminskas E: Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci USA 81: 5694– 5698, 1984 69 Lindskov R, Wulf HC, Wantzin GL, Niebuhr E: Sister chromatid exchange in patients treated with methotrexate for psoriasis. J Invest Dermatol 82: 458– 459, 1984 70 Matheson D, Brunsick D, Carrans R: Comparison of relative mutagenic activity for eight antineoplastic drugs in the Ames salmonella/microsome and TK +/– mouse lymphoma assays. Drug Chem Toxicol 1: 227– 304, 1978 71 Banerjee A, Benedict WF: Production of sister chromatid exchanges by various cancer chemotherapeutic agents. Cancer Res 39: 797– 799, 1979 72 Benedict WF, Banerjee A, Gardner A, Jones PA: Induction of morphological transformation in mouse C3H/10T0.5 clone 8 cells and chromosomal damage in hamster A (T') C1-3 cells by cancer chemotherapeutic agents. Cancer Res 37: 2202– 2208, 1977 73 Colburn KK, Cao JD: Thymoma associated with rheumatoid arthritis in a patient taking methotrexate. J Rheumatol 13: 437– 439, 1986 74 Craig SR, Rosenberg EW: Methotrexate-induced carcinoma. Arch Dermatol 103: 505– 506, 1971 75 Nyfors A, Jensen H: Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. Dermatologica 167: 260– 261, 1983 76 Rustin GJS, Rustin F, Dent J, Booth M, Salt S, Bagshawe KD: No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 308: 473– 476, 1983 77 Goldman ID, Matherly LH, Fabre G: Methotrexate, aminopterin and 7-hydroxymethotrexate, Recent Concepts in the Cellular Pharmacology of 4-Aminoantifolates in Development of Targen-O Noted Anticancer Drugs. Edited by Y-C Xheng. New York, Raven Press, 1983, pp 19– 40 78 Baugh CM, Kramdieck CL, Nair MG: Polygammaglutamyl derivatives of methotrexate. Biochem Biophys Res Commun 52: 27– 34, 1973 79 Galvin J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17: 105– 110, 1980 80 Huennekens FM, Vitolis KS, Whiteley JM, Neef VG: Dihydrofolate reductase. Methods Cancer Res 13: 199– 225, 1976 81 Goldman ID, Matherly LH: The cellular pharmacology of methotrexate. Pharmacol Ther 28: 77– 102, 1985 82 McBurney MW, Whitmore GF: Mechanism of growth inhibition by methotrexate. Cancer Res 35: 586– 590, 1975 83 Allegia CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260: 9720– 9726, 1986 84 Allegia CJ, Fine RL, Drake JC, Chabner BA: The effect of methotrexate in intracellular folate pools in human MCF-7 breast cancer cells. J Biol Chem 261: 6748– 6485, 1986 85 Bertino Jr: The mechanism of action of the folate antagonists in man. Cancer Res 39: 293– 304, 1979 86 Rodenhuis S, McGaire JJ, Narayanan R, Bertino Jr: Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemia cells. Cancer Res (in press) 87 Rodenhuis S, Kremer JM, Bertino Jr: Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum 30: 369– 374, 1987 88 Matheson DS, Greet B, Hoar DI: The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J Immunol 131: 1619– 1621, 1983 89 Miyasaka N, Nakamura T, Russell IJ, Talal N: Interleukin-2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 31: 109– 117, 1984 90 Combe B, Pope RM, Fischbach M, Darnell B, Baron S, Talal N: Interleukin-2 rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 59: 520– 528, 1985 91 Cream JJ, Pole DS: The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 102: 557– 563, 1980 92 Welles WL, Silkworth J, Oronsky AL, Kerwar SS, Galivan J: Studies on the effect of low dose methotrexate on rat adjuvant arthritis. J Rheumatol 12: 904– 906, 1985 93 Kremer JM: Lymphocyte subset analysis after longterm methotrexate therapy for rheumatoid arthritis (abstract). Arthritis Rheum (suppl) 29 (4): S75, 1986 94 Johnson CA, Russell AS, Kovithavougs T, Dasgupta M: Measures of immunologic and inflammatory responses in vitro in rheumatoid patients treated with methotrexate. J Rheumatol 13: 294– 296, 1986 95 O'Meara A, Headon B, Reen DJ: Effect of methotrexate on the immune responses in children with acute lymphatic leukemia. Immunopharmacology 9: 33– 38, 1985 96 Olsen NJ, Callahan LF, Pincus T: Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 30: 481– 488, 1987 97 Sikes DH, Cory JG, Vasey FB, Germain BF, Espinoza LR: Lack of inhibition of thymidylate synthetase activity with low dose oral methotrexate in rheumatoid arthritis (abstract). Arthritis Rheum (suppl) 29 (4): S18, 1986 98 O'Callaghan JW, Bretscher P, Russell AS: The effect of low-dose chronic intermittent parenteral methotrexate on delayed type hypersensitivity and acute inflammation in a mouse model. J Rheumatol 13: 710– 714, 1986 Citing Literature Volume31, Issue3March 1988Pages 305-314 ReferencesRelatedInformation
Referência(s)